An overlooked mental health challenge faced by new mothers. A powerful new drug could be critical in fighting back. It should have been an obvious match. Yet things may not turn out that way because of pharma industry’s pricing vagaries as well as the lack of conversation around the condition itself.
Related Posts
An army of 12,000 medical reps: How Rajeev Juneja flexed Mankind to the pharma top order
Synopsis While Ramesh Juneja has led Mankind Pharma for three decades, his brother Rajeev kept in tow and took charge of key operations. Suave and yet rustic, the younger Juneja has a unique style to push the 12,000-strong team of medical representatives in a fiercely competitive market and can sense the pulse of his people […]
Sun Pharma’s earnings pace is likely to slow down as it takes two steps back for a leap forward
A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai, India. Synopsis Dilip Shanghvi’s Sun Pharma made a bold move entering the specialty-drugs business which has started to pay it back. Now, the company is scouting acquisitions and augmenting its in-house R&D to enhance its specialty-drugs […]
PharmEasy has skipped the growth pill for profitability. This may lead to side effects
Healthtech company PharmEasy seems to finally be able to hold its head above water. The unicorn, which has been struggling with slowing growth, debt burden, and steep valuation cuts by investors, had something to cheer about when it turned Ebitda (earnings before interest, taxes, depreciation and amortisation) profitable in April this year. For venture capital […]
